HR = 0.35
(95% CI: 0.25, 0.49)
P
<.00001
Number at Risk
Olaparib
136
106
53
24
7
0
Placebo
129
72
24
7
1
0
Study 19: Met PFS Primary Endpoint
0
0.6
0.8
0.9
0
0.1
0.2
0.3
0.4
0.5
0.7
1.0
3
6
9
12
15
Probability
of
PFS
Time From Randomisation, Months
Placebo
Olaparib
Olaparib
N = 136
Placebo
N = 129
Median
(95%CI)
8.4 mo
(7.4, 11.5)
4.8 mo
(4.0, 5.5)
Ledermann J
et al
.
N Engl J Med
2012;366:1382–1392
